Vividion Therapeutics

OverviewSuggest Edit

Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.

TypePrivate
Founded2013
HQPrinceton, US
Websitevividion.com

Key People/Management at Vividion Therapeutics

Thomas Daniel

Thomas Daniel

Executive Chairman

Vividion Therapeutics Office Locations

Vividion Therapeutics has an office in Princeton
Princeton, US (HQ)
Princeton, NJ, USA
Show all (1)

Vividion Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

Vividion Therapeutics total Funding

$236.5 m

Vividion Therapeutics latest funding size

$82 m

Time since last funding

5 months ago

Vividion Therapeutics investors

Vividion Therapeutics's latest funding round in April 2019 was reported to be $82 m. In total, Vividion Therapeutics has raised $236.5 m
Show all financial metrics

Vividion Therapeutics Online and Social Media Presence

Embed Graph

Vividion Therapeutics News and Updates

Vividion Therapeutics Expands Leadership Team with the Appointments of Fred Aslan, M.D., President and Chief Business Officer, and Larry Burgess, Ph.D., Head of Chemistry

SAN DIEGO, Sept. 25, 2018 /PRNewswire/ -- Vividion Therapeutics, a biotechnology company applying revolutionary proteomics and chemistry platforms to discover and develop novel small molecule therapeutics, today announced the appointments of Fred Aslan, M.D. as President and Chief...

Vividion Therapeutics Blogs

Vividion Therapeutics Announces $82 Million Series B Financing

Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing Bolsters capital to advance lead programs into the clinic and broaden early-stage pipeline of therapeutics against previously intractable drug targets Financing round led by Nextech Invest SAN DIEGO, CA, April 30, 2019. Vi…

Vividion Therapeutics Frequently Asked Questions

  • When was Vividion Therapeutics founded?

    Vividion Therapeutics was founded in 2013.

  • Who are Vividion Therapeutics key executives?

    Vividion Therapeutics's key executives are Thomas Daniel.

  • Who are Vividion Therapeutics competitors?

    Competitors of Vividion Therapeutics include CTD Holdings, Enanta Pharmaceuticals and CEL-SCI.

  • Where is Vividion Therapeutics headquarters?

    Vividion Therapeutics headquarters is located at Princeton, NJ, USA, Princeton.

  • Where are Vividion Therapeutics offices?

    Vividion Therapeutics has an office in Princeton.

  • How many offices does Vividion Therapeutics have?

    Vividion Therapeutics has 1 office.